DE3925109A1 - Extrakte der pflanze acanthospermum hispidum - Google Patents
Extrakte der pflanze acanthospermum hispidumInfo
- Publication number
- DE3925109A1 DE3925109A1 DE3925109A DE3925109A DE3925109A1 DE 3925109 A1 DE3925109 A1 DE 3925109A1 DE 3925109 A DE3925109 A DE 3925109A DE 3925109 A DE3925109 A DE 3925109A DE 3925109 A1 DE3925109 A1 DE 3925109A1
- Authority
- DE
- Germany
- Prior art keywords
- extract
- plant
- hispidum
- acanthospermum
- extracts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 88
- 241001073386 Acanthospermum hispidum Species 0.000 title claims abstract description 19
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 16
- 241000124008 Mammalia Species 0.000 claims abstract description 10
- 241000700605 Viruses Species 0.000 claims abstract description 10
- 230000005855 radiation Effects 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 238000011321 prophylaxis Methods 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 5
- 230000001177 retroviral effect Effects 0.000 claims abstract description 4
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 3
- 239000002955 immunomodulating agent Substances 0.000 claims abstract description 3
- 230000002584 immunomodulator Effects 0.000 claims abstract description 3
- 229940121354 immunomodulator Drugs 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 241000196324 Embryophyta Species 0.000 claims description 11
- 230000006378 damage Effects 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 241001073385 Acanthospermum Species 0.000 claims description 7
- 230000000840 anti-viral effect Effects 0.000 claims description 5
- 230000000798 anti-retroviral effect Effects 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 230000002519 immonomodulatory effect Effects 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 101150091111 ACAN gene Proteins 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 241001430294 unidentified retrovirus Species 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- 230000006023 anti-tumor response Effects 0.000 claims 1
- 239000006286 aqueous extract Substances 0.000 abstract description 3
- 206010025482 malaise Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 31
- 241000699666 Mus <mouse, genus> Species 0.000 description 28
- 210000002540 macrophage Anatomy 0.000 description 21
- 206010028980 Neoplasm Diseases 0.000 description 19
- 239000006228 supernatant Substances 0.000 description 17
- 230000035755 proliferation Effects 0.000 description 14
- 239000013049 sediment Substances 0.000 description 14
- 210000001185 bone marrow Anatomy 0.000 description 13
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 241000711975 Vesicular stomatitis virus Species 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 210000004989 spleen cell Anatomy 0.000 description 9
- 201000008808 Fibrosarcoma Diseases 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 229940104230 thymidine Drugs 0.000 description 8
- 102000014150 Interferons Human genes 0.000 description 7
- 108010050904 Interferons Proteins 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 229940079322 interferon Drugs 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
- 235000011130 ammonium sulphate Nutrition 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 108091092356 cellular DNA Proteins 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- KNJDBYZZKAZQNG-UHFFFAOYSA-N lucigenin Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.C12=CC=CC=C2[N+](C)=C(C=CC=C2)C2=C1C1=C(C=CC=C2)C2=[N+](C)C2=CC=CC=C12 KNJDBYZZKAZQNG-UHFFFAOYSA-N 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 208000003265 stomatitis Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 241000208838 Asteraceae Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 208000004898 Herpes Labialis Diseases 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 101710189714 Major cell-binding factor Proteins 0.000 description 2
- 206010067152 Oral herpes Diseases 0.000 description 2
- 102100030000 Recombining binding protein suppressor of hairless Human genes 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 125000000972 4,5-dimethylthiazol-2-yl group Chemical group [H]C([H])([H])C1=C(N=C(*)S1)C([H])([H])[H] 0.000 description 1
- 102000004008 5'-Nucleotidase Human genes 0.000 description 1
- 108700004024 5'-Nucleotidase Proteins 0.000 description 1
- ITZMJCSORYKOSI-AJNGGQMLSA-N APGPR Enterostatin Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 ITZMJCSORYKOSI-AJNGGQMLSA-N 0.000 description 1
- 229920001076 Cutan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- DUEDDXAOCLBLLA-UHFFFAOYSA-N Melampolide Natural products CC(=O)OCC=C(/C)C(=O)OC1CC(=C/CCC(=CC2OC(=O)C(=C)C12)C)C=O DUEDDXAOCLBLLA-UHFFFAOYSA-N 0.000 description 1
- 241000711466 Murine hepatitis virus Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241001611093 Stimula Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001532 anti-fungicidal effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- HRYLQFBHBWLLLL-AHNJNIBGSA-N costunolide Chemical compound C1CC(/C)=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]21 HRYLQFBHBWLLLL-AHNJNIBGSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000003958 fumigation Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 150000008195 galaktosides Chemical class 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000008095 long lasting therapeutic effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229940041290 mannose Drugs 0.000 description 1
- GGGDNPWHMNJRFN-UHFFFAOYSA-N metrizoic acid Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I GGGDNPWHMNJRFN-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- MUUHXGOJWVMBDY-UHFFFAOYSA-L tetrazolium blue Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 MUUHXGOJWVMBDY-UHFFFAOYSA-L 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000005925 vesicular stomatitis Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3925109A DE3925109A1 (de) | 1989-07-28 | 1989-07-28 | Extrakte der pflanze acanthospermum hispidum |
| JP2510688A JPH04500820A (ja) | 1989-07-28 | 1990-07-27 | 植物アカンソスペルマム・ヒスピダムの抽出物 |
| AT90910726T ATE112489T1 (de) | 1989-07-28 | 1990-07-27 | Extrakte von acanthospermum hispidum-pflanzen. |
| ES90910726T ES2061053T3 (es) | 1989-07-28 | 1990-07-27 | Extractos de la planta acantospermum hispidum. |
| DE69013134T DE69013134T2 (de) | 1989-07-28 | 1990-07-27 | Extrakte von acanthospermum hispidum-pflanzen. |
| CA002035031A CA2035031A1 (en) | 1989-07-28 | 1990-07-27 | Extracts of the acanthospermum hispidum plant |
| US07/659,313 US5256416A (en) | 1989-07-28 | 1990-07-27 | Extracts of the Acanthospermum hispidum plant |
| EP90910726A EP0436690B1 (en) | 1989-07-28 | 1990-07-27 | Extracts of the acanthospermum hispidum plant |
| AU60736/90A AU635553B2 (en) | 1989-07-28 | 1990-07-27 | Extracts of the acanthospermum hispidum plant |
| PCT/EP1990/001231 WO1991001741A1 (en) | 1989-07-28 | 1990-07-27 | Extracts of the acanthospermum hispidum plant |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3925109A DE3925109A1 (de) | 1989-07-28 | 1989-07-28 | Extrakte der pflanze acanthospermum hispidum |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3925109A1 true DE3925109A1 (de) | 1991-01-31 |
| DE3925109C2 DE3925109C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1992-10-15 |
Family
ID=6386098
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3925109A Granted DE3925109A1 (de) | 1989-07-28 | 1989-07-28 | Extrakte der pflanze acanthospermum hispidum |
| DE69013134T Expired - Fee Related DE69013134T2 (de) | 1989-07-28 | 1990-07-27 | Extrakte von acanthospermum hispidum-pflanzen. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69013134T Expired - Fee Related DE69013134T2 (de) | 1989-07-28 | 1990-07-27 | Extrakte von acanthospermum hispidum-pflanzen. |
Country Status (9)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8795627B2 (en) | 2007-03-21 | 2014-08-05 | Raptor Pharmaceuticals Inc. | Treatment of liver disorders by administration of RAP conjugates |
| US20120077778A1 (en) | 2010-09-29 | 2012-03-29 | Andrea Bourdelais | Ladder-Frame Polyether Conjugates |
| WO2015189658A1 (en) * | 2014-06-10 | 2015-12-17 | Natarajan Deepa | Acanthospermum hispidum composition for the treatment of cancer and methods for its manufacture |
| US20230060934A1 (en) * | 2021-08-25 | 2023-03-02 | Michael Wayne Dockery | Botanical antiviral nutritional supplement |
-
1989
- 1989-07-28 DE DE3925109A patent/DE3925109A1/de active Granted
-
1990
- 1990-07-27 DE DE69013134T patent/DE69013134T2/de not_active Expired - Fee Related
- 1990-07-27 US US07/659,313 patent/US5256416A/en not_active Expired - Fee Related
- 1990-07-27 AU AU60736/90A patent/AU635553B2/en not_active Ceased
- 1990-07-27 AT AT90910726T patent/ATE112489T1/de active
- 1990-07-27 EP EP90910726A patent/EP0436690B1/en not_active Expired - Lifetime
- 1990-07-27 JP JP2510688A patent/JPH04500820A/ja active Pending
- 1990-07-27 ES ES90910726T patent/ES2061053T3/es not_active Expired - Lifetime
- 1990-07-27 WO PCT/EP1990/001231 patent/WO1991001741A1/en active IP Right Grant
- 1990-07-27 CA CA002035031A patent/CA2035031A1/en not_active Abandoned
Non-Patent Citations (6)
| Title |
|---|
| ALTSCHUL, S.v.R.: Drugs and Food from Little- Known Plants, Harward Univ. Press, Mass. 1973, S. 315 * |
| Phytochemistry, 1976, 15, S. 1776-1778 * |
| Phytochemistry, 1979, 18, S. 625-630 * |
| Planta Medica, 1971, 20, 2, S. 118-123 * |
| Planta Medica, 1972, 22, 2, S. 136-139 * |
| Planta Medica, 1986, S. 154-155 * |
Also Published As
| Publication number | Publication date |
|---|---|
| DE3925109C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1992-10-15 |
| DE69013134D1 (de) | 1994-11-10 |
| ATE112489T1 (de) | 1994-10-15 |
| EP0436690B1 (en) | 1994-10-05 |
| DE69013134T2 (de) | 1995-02-16 |
| JPH04500820A (ja) | 1992-02-13 |
| AU6073690A (en) | 1991-03-11 |
| ES2061053T3 (es) | 1994-12-01 |
| WO1991001741A1 (en) | 1991-02-21 |
| EP0436690A1 (en) | 1991-07-17 |
| US5256416A (en) | 1993-10-26 |
| CA2035031A1 (en) | 1991-01-29 |
| AU635553B2 (en) | 1993-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3227262C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE68920019T2 (de) | Aloe-zusammensetzungen und deren verwendungen. | |
| DE3027105A1 (de) | Verfahren zur herstellung eines die proliferation und differenzierung menschlicher granulopoetischer stammzellen stimulierenden faktors | |
| DE2441454A1 (de) | Verfahren zur herstellung eines heilmittels fuer leukaemie | |
| DE3421789C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE69434093T2 (de) | Substanz mit immunonodulierender wirkung und zur verringerung der disfunktion des gewebezellenregelungssystems | |
| DE69634530T2 (de) | Antivirales mittel und verfahren zu dessen herstellung | |
| DE4242902A1 (de) | Verfahren zur Herstellung von Lektinkonzentraten aus Mistelextrakten und daraus hergestellte standardisierte Präparate zur Erhöhung der natürlichen Immunresistenz und für die Verwendung in der Tumor-Therapie | |
| DE60124591T2 (de) | Agastache rugosa extrakt mit entzündungshemmender wirkung und antiatherogener wirkung | |
| DE3925109C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE3504940C2 (de) | Multipotente Paramunitätsmediatoren, Verfahren zu ihrer Herstellung und diese Mediatoren enthaltende Arzneimittel | |
| EP0595297B1 (de) | Ligninpolymerzusammensetzung zur Behandlung von Hautproblemen | |
| CH650154A5 (de) | Wasserloesliche, biologisch aktive fraktion aus dem interzellularen medium des knochenmarks, verfahren zu deren gewinnung und diese enthaltende pharmazeutische zubereitung. | |
| DE3141970C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE3123830A1 (de) | "antivirussubstanz und verfahren zu ihrer herstellung" | |
| DE69526096T2 (de) | Wachstumsregulator | |
| DE69902866T2 (de) | Extrakte aus kuhausscheidungen mit antikrebs- und antiinflammatorischer wirksamkeit sowie verfahren zu deren herstellung | |
| EP0315182B1 (de) | Arzneimittel mit einem Gehalt an einer Polysaccharide enthaltenden Komponente aus Thujapflanzen als aktivem Wirkstoff | |
| DE4206233C1 (en) | Use of Bellis Perennis extract - for treatment and prevention of hypoxia caused by e.g. cerebral ischaemia | |
| DE4010368A1 (de) | Mittel zur bekaempfung von aids-viren und anderen viren | |
| DE745419C (de) | Verfahren zur Herstellung eines spezifischen Heilmittels gegen Hautekzeme | |
| EP0241498B1 (de) | Schmerzstillendes und entzündungshemmendes arzneimittel auf pflanzlicher basis | |
| DE2708666C3 (de) | Arzneimittel mit immunoregulativer und antiphlogistischer Wirkung | |
| DE3249946C2 (de) | hTNF-haltiges therapeutisches Mittel gegen maligne Tumoren und dessen Verwendung | |
| DE19844022C1 (de) | Verwendung von eisenbindenden Glycoproteinen und/oder 10-Hydroxy-2-decensäure in Verbindung mit Thymochinon zur Behandlung von AIDS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: MERCK PATENT GMBH, 64293 DARMSTADT, DE |
|
| 8339 | Ceased/non-payment of the annual fee |